e-therapeutics Announces Business Updates and Interim Results
31 oct. 2024 09h00 HE
|
e-therapeutics plc
LONDON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced business...
Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
08 août 2024 01h32 HE
|
Recursion Pharmaceuticals
Salt Lake City, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will provide business updates...
Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th
05 août 2024 16h01 HE
|
Recursion Pharmaceuticals
Salt Lake City, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide...
Recursion to Participate in Upcoming Investor Conferences
03 juin 2024 09h00 HE
|
Recursion Pharmaceuticals
SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
Evaxion Announces Business Update and First Quarter 2024 Financial Results
28 mai 2024 08h21 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, May 28, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™...
Recursion to Participate in Upcoming Investor Conferences
01 mai 2024 08h01 HE
|
Recursion Pharmaceuticals
SALT LAKE CITY, May 01, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
Recursion to Participate in Upcoming Investor Conference
02 avr. 2024 08h00 HE
|
Recursion Pharmaceuticals
SALT LAKE CITY, April 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
19 mars 2024 07h30 HE
|
Evaxion Biotech
The proprietary AI-Immunology™ platform brings the potential for a new era in vaccine discovery, design and development using advanced AI and machine learning technologiesAI-Immunology™ outcompetes...
Recursion to Participate in Upcoming Investor Conferences
01 mars 2024 07h59 HE
|
Recursion Pharmaceuticals
SALT LAKE CITY, March 01, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
IMU Biosciences secures £11.5 million in Series A funding to revolutionise immune powered precision medicine
24 janv. 2024 03h00 HE
|
IMU Biosciences
Board strengthened with appointments of Tim Haines (Abingworth) as Non-executive Chair and Dr Oliver Nussbaumer (co-founder of GammaDelta Therapeutics and Adaptate Biotherapeutics) and Dr Inga Deakin...